Want to see CAMP full AI Analyst Report?
Total Valuation
CAMP4 Therapeutics Corporation has a market cap or net worth of $266.07M. The enterprise value is $168.40.
Market Cap$266.07M
Enterprise Value$168.40
Share Statistics
CAMP4 Therapeutics Corporation has 62,753,200 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding62,753,200
Owned by Insiders20.61%
Owned by Institutions34.74%
Financial Efficiency
CAMP4 Therapeutics Corporation’s return on equity (ROE) is -1.69 and return on invested capital (ROIC) is -50.75%.
Return on Equity (ROE)-1.69
Return on Assets (ROA)-0.68
Return on Invested Capital (ROIC)-50.75%
Return on Capital Employed (ROCE)-0.51
Revenue Per Employee72.88K
Profits Per Employee-1.68M
Employee Count48
Asset Turnover0.03
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of CAMP4 Therapeutics Corporation is ―. CAMP4 Therapeutics Corporation’s PEG ratio is 6.15.
PE Ratio―
PS Ratio53.24
PB Ratio3.90
Price to Fair Value3.90
Price to FCF-6.24
Price to Operating Cash Flow-8.59
PEG Ratio6.15
Income Statement
In the last 12 months, CAMP4 Therapeutics Corporation had revenue of 3.50M and earned -80.40M in profits. Earnings per share was -2.65.
Revenue3.50M
Gross Profit1.86M
Operating Income-52.06M
Pretax Income-80.40M
Net Income-80.40M
EBITDA-50.42M
Earnings Per Share (EPS)-2.65
Cash Flow
In the last 12 months, operating cash flow was -28.59M and capital expenditures -129.00K, giving a free cash flow of -28.72M billion.
Operating Cash Flow-28.59M
Free Cash Flow-28.72M
Free Cash Flow per Share-0.46
Dividends & Yields
CAMP4 Therapeutics Corporation pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta2.01
52-Week Price Change54.18%
50-Day Moving Average4.10
200-Day Moving Average4.51
Relative Strength Index (RSI)50.76
Average Volume (3m)283.90K
Important Dates
CAMP4 Therapeutics Corporation upcoming earnings date is Nov 19, 2026, After Close (Confirmed).
Last Earnings DateAug 14, 2026
Next Earnings DateNov 19, 2026
Ex-Dividend Date―
Financial Position
CAMP4 Therapeutics Corporation as a current ratio of 7.35, with Debt / Equity ratio of -342.28%
Current Ratio7.35
Quick Ratio7.35
Debt to Market Cap0.01
Net Debt to EBITDA2.13
Interest Coverage Ratio0.00
Taxes
In the past 12 months, CAMP4 Therapeutics Corporation has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
CAMP4 Therapeutics Corporation EV to EBITDA ratio is -1.56, with an EV/FCF ratio of -2.64.
EV to Sales22.50
EV to EBITDA-1.56
EV to Free Cash Flow-2.64
EV to Operating Cash Flow-2.66
Balance Sheet
CAMP4 Therapeutics Corporation has $87.13M in cash and marketable securities with $2.37M in debt, giving a net cash position of $84.76M billion.
Cash & Marketable Securities$87.13M
Total Debt$2.37M
Net Cash$84.76M
Net Cash Per Share$1.35
Tangible Book Value Per Share$1.57
Margins
Gross margin is 77.80%, with operating margin of -1488.31%, and net profit margin of -2298.54%.
Gross Margin77.80%
Operating Margin-1488.31%
Pretax Margin-2298.54%
Net Profit Margin-2298.54%
EBITDA Margin-1441.45%
EBIT Margin-1488.31%
Analyst Forecast
The average price target for CAMP4 Therapeutics Corporation is $9.75, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$9.75
Price Target Upside132.14% Upside
Analyst ConsensusStrong Buy
Analyst Count5
Revenue Growth Forecast40.21%
EPS Growth Forecast13.40%